Earnings Call Summary | CureVac(CVAC.US) Q4 2023 Earnings Conference
Earnings Call Summary | CureVac(CVAC.US) Q4 2023 Earnings Conference
The following is a summary of the CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript:
以下是CureVac N.V.（CVAC）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
CureVac reported solid cash position of €402.5 million at the end of 2023 and expects to extend its cash runway into Q4 of 2025
Implemented cost-saving program that included a reduction of 150 positions and reduced operating costs, thus increasing efficiency.
During 2023, revenues increased by €10.9 million to €22.6 million for Q4 but decreased by €13.6 million to €53.8 million for the year, primarily due to lower revenues from its collaboration with GSK.
Operating loss amounted to €88 million for Q4 2023, and increased by €24.7 billion to €274.2 million for the 12 months.
CureVac報告稱，截至2023年底，穩健的現金狀況爲4.025億歐元，預計其現金流將延長至2025年第四季度
實施了節省成本的計劃，其中包括減少 150 個職位和降低運營成本，從而提高效率。
2023年期間，第四季度的收入增長了1,090萬歐元，至2,260萬歐元，但同年下降了1,360萬歐元，至5,380萬歐元，這主要是由於與葛蘭素史克合作的收入減少。
2023年第四季度的營業虧損爲8,800萬歐元，在過去12個月中增長了247億歐元，達到2.742億歐元。
Business Progress:
業務進展：
CureVac has focused on advancing its clinical trials and development pipelines in infectious diseases and oncology.
Launched a new Phase 1/2 study in avian flu treatment with partner GSK, and reported interim data from ongoing programs in seasonal flu and COVID-19.
Oncology studies have successfully completed Phase 1 in patients with resected glioblastoma and plans to initiate the next part of the study in mid-2024.
Increased focus on oncology innovation through partnership with MD Anderson and hiring of a new Chief Business Officer.
Significant strides recorded in automated manufacturing of GMP-grade RNA vaccines and therapeutics with the mRNA printer.
CureVac一直專注於推進其傳染病和腫瘤學的臨床試驗和開發管道。
與合作伙伴葛蘭素史克共同啓動了一項新的1/2期禽流感治療研究，並報告了正在進行的季節性流感和 COVID-19 項目的中期數據。
腫瘤學研究已成功完成對切除膠質母細胞瘤患者的第一階段，並計劃在2024年中期啓動下一部分研究。
通過與MD Anderson合作並聘請新的首席商務官，更加關注腫瘤學創新。
在使用mRNA打印機自動製造GMP級RNA疫苗和療法方面取得了重大進展。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。